title: [Drug distribution of pelvic intraarterial infusion chemotherapy by bilateral internal iliac arterial catheter placement with coil occlusion of superior, inferior gluteal and obturator arteries].
abstract: The anticancer drug distribution in pelvic arterial infusion chemotherapy with bilateral internal iliac arterial catheter placement with coil occlusion of the superior, inferior and obturator arteries was indirectly evaluated by serially performed DSA, CTA and RI on 18 patients with pelvic malignancies. The distribution was judged to be Excellent (E), defined as uniform distribution in the entire lesion alone, in 9 of 18 patients (50%) evaluated prior to the start of the arterial infusion (AI), and as Good (G), defined as uniform distribution in the entire lesion and partly on an unaffected portion, in 9 (50%). Of the 11 patients evaluated after 7 times AI, E was found in 3 patients (27%), G in 7 (64%) and Fair (F), defined as distribution with a defect in the lesion, in one patient (9%). Of the 11 patients evaluated after 14 AI, E was found in 5 (45%), G in 4 (36%) and F in 2 (18%). Of the 7 patients evaluated after 21 AI, E was found in 2 (29%), G in 4 (57%) and F in one (14%). G was found in 2 of 2 patients (100%) evaluated after 28 AI. These results suggest that this method can maintain a favorable anticancer drug distribution even after multiple sessions of AI.
authors.affiliation: Dept. of Radiology, Nara Medical University.
authors.forename: S
authors.initials: S
authors.lastname: Sakaguchi
authors.forename: H
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: N
authors.initials: N
authors.lastname: Matsuo
authors.forename: H
authors.initials: H
authors.lastname: Anai
authors.forename: A
authors.initials: A
authors.lastname: Ohkura
authors.forename: S
authors.initials: S
authors.lastname: Hirohashi
authors.forename: T
authors.initials: T
authors.lastname: Imai
authors.forename: H
authors.initials: H
authors.lastname: Ohishi
authors.forename: S
authors.initials: S
authors.lastname: Akada
authors.forename: H
authors.initials: H
authors.lastname: Morikawa
authors.forename: H
authors.initials: H
authors.lastname: Uchida
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000493:pharmacokinetics; D002081:Buttocks; D002404:Catheterization; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D005047:Etoposide / Q000008:administration & dosage / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007083:Iliac Artery; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D001761:Bleomycin; D015251:Epirubicin; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D002945:Cisplatin